Drug intelligence / Profile preview

YB-300

Development stage: Preclinical
Lead developer: Ymmunobio

Overview

YB-300 is an investigational anticancer agent described as a CEACAM1 inhibitor being developed in the preclinical stage for oncology indications. It targets carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), an immunoregulatory and adhesion molecule implicated in tumor progression and immune evasion, with the goal of modulating CEACAM1-mediated signaling to enhance antitumor immune responses and inhibit tumor growth.[1] The program was initially developed by Ymmunobio, a company focused on CEACAM1-targeted therapies for cancer.[1]

Targets

CEACAM1

Beyond the preview

Go deeper on YB-300.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YB-300.

Explore the full profile